Abstract
Neonatal chronic lung disease is an important cause of morbidity following premature birth. Surfactant abnormalities, including absence of phosphatidylglycerol and surfactant protein A deficiency, are associated with chronic lung disease. In addition, glycolipids and proteins, inhibitors of surfactant function, are present in the airways of affected patients. To date, there is information regarding the impact of exogenous surfactant on this condition, but preliminary results suggest that even a single dose of a natural surfactant at least temporarily reduces the level of supplementary oxygen requirement. Randomized controlled trials are required to evaluate whether surfactant administration will reduce chronic oxygen dependency and its associated morbidity.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Greenough, A. Neonatal chronic lung disease and exogenous surfactant therapy. Eur J Pediatr 157 (Suppl 1), S16–S18 (1998). https://doi.org/10.1007/PL00014283
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/PL00014283